Manager × security

Bain Capital Life Sciences Investors, LLC CABA holdings history

Who else holds this security? →

CABALETTA BIO INC · CUSIP 12674W109 · CIK 1703031

This is the oldest quarter open without an account, so changes against the quarter before it are withheld. Sign in to see them.
Citable facts

As of 2026-06-30, Bain Capital Life Sciences Investors, LLC reported 17.24M CABA (shares), valued at $53.62M, or 3.19% of its reported non-derivative portfolio. Filed 2026-08-14.

Verify history & sources →
Portfolio weight and quantity history
Reported portfolio weight
3.19%
Shares
17.24M
17,241,445
Reported value
$53.62M
USD

Shares increased 78.17%; reported value increased 105.98%, and weight changed +0.84 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.

Left: % · Right: Shares · Independently scaled axes

Exact data and methodology

Axes scale independently; a crossing does not mean equal values. Weight uses each quarter's total reported non-derivative value. Same CUSIP; missing quarters are gaps, not zero. Revised history may include later disclosures.

QuarterWeightQuantitySource
Q2 20263.19%17,241,445SEC filing ↗Filed Aug 14, 2026
Q1 20262.35%9,677,125SEC filing ↗Filed May 15, 2026
Q4 20251.62%9,677,125SEC filing ↗Filed Feb 17, 2026
Q3 20251.50%9,677,125SEC filing ↗Filed Nov 14, 2025
Q2 20251.84%9,677,125SEC filing ↗Filed Aug 14, 2025
Q1 20250.57%2,760,888SEC filing ↗Filed May 15, 2025
Q4 20240.74%2,760,888SEC filing ↗Filed Feb 14, 2025
Q3 20241.36%2,760,888SEC filing ↗Filed Nov 14, 2024
Q2 20241.35%1,649,964SEC filing ↗Filed Aug 12, 2024
Q1 20242.22%1,617,364SEC filing ↗Filed May 15, 2024
Q4 20234.35%2,000,000SEC filing ↗Filed Feb 13, 2024

History & evidence by quarter

QuarterWeightQuantityValueChange explainedSource
Q4 20234.35%2,000,000$45.40MThe prior quarter is outside the free window. Sign in for the comparison.SEC filing ↗
Filed Feb 13, 2024
Q1 20242.22%1,617,364$27.59MShares decreased 19.13%; reported value decreased 39.22%, and weight changed -2.13 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 15, 2024
Q2 20241.35%1,649,964$12.34MShares increased 2.02%; reported value decreased 55.27%, and weight changed -0.87 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 12, 2024
Q3 20241.36%2,760,888$13.03MShares increased 67.33%; reported value increased 5.59%, and weight changed +0.01 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Nov 14, 2024
Q4 20240.74%2,760,888$6.27MShares unchanged; reported value decreased 51.91%, and weight changed -0.62 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Feb 14, 2025
Q1 20250.57%2,760,888$3.82MShares unchanged; reported value decreased 38.99%, and weight changed -0.17 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 15, 2025
Q2 20251.84%9,677,125$14.71MShares increased 250.51%; reported value increased 284.67%, and weight changed +1.27 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 14, 2025
Q3 20251.50%9,677,125$22.64MShares unchanged; reported value increased 53.95%, and weight changed -0.34 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Nov 14, 2025
Q4 20251.62%9,677,125$21.19MShares unchanged; reported value decreased 6.41%, and weight changed +0.12 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Feb 17, 2026
Q1 20262.35%9,677,125$26.03MShares unchanged; reported value increased 22.83%, and weight changed +0.73 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 15, 2026
Q2 20263.19%17,241,445$53.62MShares increased 78.17%; reported value increased 105.98%, and weight changed +0.84 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 14, 2026
Bain Capital Life Sciences Investors, LLC · CABALETTA BIO INC

Take these holdings further.

This page includes 11 of 11 reported holdings. Sign in to look up the full history beyond 3 years, use advanced screening & filtering, download CSV, and get the complete set through the Akkru API.

  • Download CSV
  • Earlier quarters
  • Advanced screening & filtering
  • API & AI access
Already have an account?

+ New accounts get free API credits to explore data beyond ownership filings.

For AI agents & developers

The initial HTML of this page carries its exact data as script#research-data (JSON): values, units, scope, preview limits and SEC sources. Read it directly, no script or API key needed; script#research-access says what needs an account.

Without an account: the last 3 years, with the row caps stated on the page. A free account opens all history on file on these pages and the CSV of what a page shows. Rows beyond the caps and bulk retrieval go through the authenticated API / MCP.

MCP  https://api.akkrudata.ai/mcp

get_institutional_portfolio
{"cik":"1703031","quarter":"2026Q2","cusip":"12674W109"}

get_institutional_manager_history
{"cik":"1703031","page_size":100}

Connect to MCP with OAuth and follow the returned pagination. Credits and usage limits depend on the account.

MCP endpoint
https://api.akkrudata.ai/mcp
API / MCP documentation
/documents
llms.txt
/llms.txt
Sources, coverage & how to read this data

Figures are as reported to the SEC and merged with later amendments where Akkru could match them. Preview limits apply to what is listed, not to the totals, which come from the complete reported data. Nothing is zero-filled: a missing quarter or month is shown as missing.

13F reports quarter-end long positions in securities traded on US exchanges, filed by managers holding at least $100 million of such securities; it is not the manager's full portfolio, not assets under management, and value changes are not returns. Weights use the reported total value as denominator. Option rows show notional value, not premium or net exposure. Amendments are merged into the quarter when Akkru could match them.